Indiana ranks 7th nationally for adult obesity at 36.8%. Type 2 diabetes affects over 700,000 Hoosiers. Marion County (Indianapolis) alone has over 150,000 adults eligible for GLP-1 therapy. Across metro areas like Indianapolis, Fort Wayne, Evansville, South Bend, obesity-related conditions including type 2 diabetes, hypertension, and cardiovascular disease affect hundreds of thousands of Indiana residents every year.
GLP-1 receptor agonists — semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) — are FDA-approved prescription medications that produce average weight loss of 15–22% of body weight in clinical trials, with proven reductions in cardiovascular event risk. Thanks to Indiana's telehealth law (Indiana Code § 25-1-9.5), these medications are now accessible from any city or rural county in the state through a licensed online physician.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Complete a secure health questionnaire from anywhere in Indiana — Indianapolis, Fort Wayne, Evansville, South Bend, or any rural county. Takes under 10 minutes.
A board-certified MD licensed in Indiana reviews your health profile and conducts a HIPAA-compliant telehealth consultation — within 24–48 hours.
If approved, your GLP-1 medication ships from a licensed US pharmacy directly to your Indiana address — no pharmacy trip, no waiting room.
Licensed telehealth GLP-1 providers serve every corner of Indiana. Select your city below for local information and to start your consultation.
Whether you live in urban Marion County, or a rural county, our Indiana-licensed telehealth providers can prescribe GLP-1 medications online. Choose your county:
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Yes. Indiana telehealth law (Indiana Code § 25-1-9.5) explicitly permits licensed physicians to prescribe medications — including GLP-1 receptor agonists — via telemedicine after a valid patient-physician relationship is established through an online consultation. You do not need to visit a clinic in person.
Indiana has an adult obesity rate of 36.8%, ranking 7th highest nationally in the United States. Cities such as Indianapolis, Fort Wayne, Evansville see high rates of obesity-related conditions including type 2 diabetes and cardiovascular disease. GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are clinically proven to reduce body weight by 15–22% and improve metabolic health markers.
Indiana-licensed telehealth providers can prescribe all FDA-approved GLP-1 medications, including semaglutide (Ozempic for diabetes, Wegovy for weight loss), tirzepatide (Mounjaro for diabetes, Zepbound for weight loss), and liraglutide (Saxenda for weight loss, Victoza for diabetes). Eligibility is assessed individually during your consultation.
Most Indiana patients complete their free health assessment online and receive a physician consultation within 24–48 hours. If approved, your prescription is sent to a licensed US pharmacy and medications typically arrive within 3–5 business days by home delivery — no in-person pharmacy visit required.
Indiana Medicaid (HIP 2.0) may cover GLP-1 medications when prescribed for FDA-approved type 2 diabetes indications. Coverage for weight loss indications (Wegovy, Zepbound) varies by commercial insurance plan. Manufacturer patient assistance and savings programs can significantly reduce out-of-pocket costs for eligible Indiana residents who do not have coverage.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
